Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson(Vanderbilt University), Christine M. Lovly(Vanderbilt University), Ryan J. Sullivan(Dana-Farber Cancer Institute), Justin Cates(Vanderbilt University Medical Center), Yuting He(Singapore-MIT Alliance for Research and Technology), Harlan Robins(Adaptive Biotechnologies (United States)), Yaomin Xu(Vanderbilt University Medical Center), James Sun(GlobalFoundries (United States)), Matthew J. Rioth(Vanderbilt University Medical Center), Erik Yusko(Adaptive Biotechnologies (United States)), Dennie T. Frederick(Brigham and Women's Hospital), Igor Puzanov(Vanderbilt University Medical Center), Zachary R. Chalmers(Foundation Medicine (United States)), Sohail Balasubramanian(GlobalFoundries (United States)), Yu Shyr(Vanderbilt University), Riley Ennis(GlobalFoundries (United States)), Garrett M. Frampton(Foundation Medicine (United States)), Jeffrey A. Sosman(Palmetto Hematology Oncology), Xingyi Guo(Vanderbilt University Medical Center), Jeffrey S. Ross(Albany Medical Center Hospital), Siraj M. Ali(GlobalFoundries (United States)), Justin M. Balko(Vanderbilt University Medical Center), Catherine Sanders(Adaptive Biotechnologies (United States)), Vincent A. Miller(Foundation Medicine (United States)), Joel Greenbowe(GlobalFoundries (United States)), Philip J. Stephens(Foundation Medicine (United States)), David Fabrizio(Foundation Medicine (United States))
Cited by 493
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
|Genome Medicine|2017|3.7k